{"id":11055,"date":"2025-04-05T11:02:00","date_gmt":"2025-04-05T09:02:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=11055"},"modified":"2025-08-08T11:07:27","modified_gmt":"2025-08-08T09:07:27","slug":"intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/","title":{"rendered":"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Tanida+S&amp;cauthor_id=40322718\">Satoshi Tanida<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-1\">1<\/a>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Imura+N&amp;cauthor_id=40322718\">Naoto Imura<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Sasoh+S&amp;cauthor_id=40322718\">Shun Sasoh<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Kubota+Y&amp;cauthor_id=40322718\">Yoshimasa Kubota<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Ban+T&amp;cauthor_id=40322718\">Tesshin Ban<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Ando+T&amp;cauthor_id=40322718\">Tomoaki Ando<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Nakamura+M&amp;cauthor_id=40322718\">Makoto Nakamura<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup>,\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?sort=date&amp;term=Joh+T&amp;cauthor_id=40322718\">Takashi Joh<\/a><sup>\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/#full-view-affiliation-2\">2<\/a><\/sup><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>J Clin Med Res \u00a02025 Apr;17(4):240-246.\u00a0doi: 10.14740\/jocmr6188.\u00a0Epub 2025 Apr 5.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Case 1 involved a 34-year-old woman who had been diagnosed with Crohn&#8217;s disease (CD) at 30 years old. After deciding to discontinue CD treatment, she was diagnosed with moderate flare-up of CD based on disease activity and endoscopic findings. Inadequate response was seen 7 days after starting oral prednisolone (PSL) at 30 mg\/day, so combination therapy was started with intensive granulocyte and monocyte adsorptive apheresis (GMA) plus upadacitinib (UPA) at 45 mg\/day. Twelve weeks after starting this combination therapy, clinical remission and endoscopic and histological improvements of the inflamed mucosa were achieved with no adverse events. Case 2 involved a 26-year-old man who had been diagnosed with CD at 13 years old. He was diagnosed with severe flare-up of CD based on disease activity and endoscopic findings due to loss of response to double doses of infliximab (IFX). Combination therapy was started with intensive GMA plus UPA at 45 mg\/day. Twelve weeks after starting this therapy, clinical remission and endoscopic and histological improvements of the inflamed mucosa were achieved with no adverse events. The combination of intensive GMA plus UPA appears to have provided an effective therapeutic option for refractory CD in a patient with a 4-year history of CD and refractoriness to systemic corticosteroids, and in another patient with a 13-year history of CD and loss of response to IFX.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Satoshi Tanida\u00a01\u00a02,\u00a0Naoto Imura\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02 J Clin Med Res \u00a02025 Apr;17(4):240-246.\u00a0doi: 10.14740\/jocmr6188.\u00a0Epub 2025 Apr 5. Case 1 involved a 34-year-old woman who had been diagnosed with Crohn&#8217;s disease (CD) at 30 years old. After deciding to discontinue CD treatment, she was diagnosed with moderate flare-up of CD based on disease activity [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[70,276,303,159,424,465,435,605,873],"class_list":["post-11055","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anti-tnf","scientific_tags-cases","scientific_tags-combination","scientific_tags-crohns-disease","scientific_tags-gma","scientific_tags-intensive","scientific_tags-lor","scientific_tags-steroid-refractory-2","scientific_tags-upadacitinib"],"acf":{"sc_authors":"<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/40322718\/<\/a>\r\n\r\n<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12045780\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12045780\/<\/a>"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Satoshi Tanida\u00a01\u00a02,\u00a0Naoto Imura\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02 J Clin Med Res \u00a02025 Apr;17(4):240-246.\u00a0doi: 10.14740\/jocmr6188.\u00a0Epub 2025 Apr 5. Case 1 involved a 34-year-old woman who had been diagnosed with Crohn&#8217;s disease (CD) at 30 years old. After deciding to discontinue CD treatment, she was diagnosed with moderate flare-up of CD based on disease activity [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T09:07:27+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/\",\"name\":\"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2025-04-05T09:02:00+00:00\",\"dateModified\":\"2025-08-08T09:07:27+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/","og_locale":"de_DE","og_type":"article","og_title":"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte","og_description":"Satoshi Tanida\u00a01\u00a02,\u00a0Naoto Imura\u00a02,\u00a0Shun Sasoh\u00a02,\u00a0Yoshimasa Kubota\u00a02,\u00a0Tesshin Ban\u00a02,\u00a0Tomoaki Ando\u00a02,\u00a0Makoto Nakamura\u00a02,\u00a0Takashi Joh\u00a02 J Clin Med Res \u00a02025 Apr;17(4):240-246.\u00a0doi: 10.14740\/jocmr6188.\u00a0Epub 2025 Apr 5. Case 1 involved a 34-year-old woman who had been diagnosed with Crohn&#8217;s disease (CD) at 30 years old. After deciding to discontinue CD treatment, she was diagnosed with moderate flare-up of CD based on disease activity [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/","og_site_name":"Adacyte","article_modified_time":"2025-08-08T09:07:27+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/","name":"Intensive Granulocyte and Monocyte Adsorptive Apheresis Plus Upadacitinib for Induction Treatment of Refractory Crohn\u2019s Disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2025-04-05T09:02:00+00:00","dateModified":"2025-08-08T09:07:27+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-upadacitinib-for-induction-treatment-of-refractory-crohns-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/11055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=11055"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=11055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}